Coherus BioSciences Inc Cash Flow Conversion Efficiency
Coherus BioSciences Inc cash flow conversion efficiency. Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has a cash flow conversion efficiency ratio of -1.972x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-119.98 Million) by net assets ($60.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Coherus BioSciences Inc (2012–2025)
Cash flow conversion efficiency of Coherus BioSciences Inc from 2012 to 2025. This chart illustrates how Coherus BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CHRS live share price for real-time trading data and today's change.
Coherus BioSciences Inc Cash Flow Conversion Ratio Explained
Coherus BioSciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Coherus BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coherus BioSciences Inc ranked by their cash flow conversion efficiency. Also see Coherus BioSciences Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Founding Construction Development Co Ltd
TW:5533
|
-0.018x |
|
BAOZUN INC. A DL -0001
F:2BZ
|
N/A |
|
Synalloy Corporation
NASDAQ:ACNT
|
-0.066x |
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
0.022x |
|
Duluth Holdings Inc
NASDAQ:DLTH
|
0.333x |
|
Argent
JSE:ART
|
0.099x |
|
Moens Bank A/S
CO:MNBA
|
N/A |
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
0.062x |
Annual Cash Flow Conversion Efficiency for Coherus BioSciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Coherus BioSciences Inc from 2012 to 2025. Review how much free cash does Coherus BioSciences Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.01 Million | $-138.51 Million | -2.270x | -1565.96% |
| 2024-12-31 | $-131.99 Million | $-20.44 Million | 0.155x | -82.87% |
| 2023-12-31 | $-193.43 Million | $-174.88 Million | 0.904x | -48.47% |
| 2022-12-31 | $-137.42 Million | $-241.12 Million | 1.755x | +558.10% |
| 2021-12-31 | $97.73 Million | $-37.43 Million | -0.383x | -169.82% |
| 2020-12-31 | $280.97 Million | $154.15 Million | 0.549x | +103.57% |
| 2019-12-31 | $105.21 Million | $28.36 Million | 0.269x | -93.47% |
| 2018-12-31 | $-38.59 Million | $-159.27 Million | 4.127x | +162.92% |
| 2017-12-31 | $30.54 Million | $-200.29 Million | -6.559x | +49.73% |
| 2016-12-31 | $19.35 Million | $-252.54 Million | -13.049x | -183.72% |
| 2015-12-31 | $-6.93 Million | $-107.99 Million | 15.585x | +4448.32% |
| 2014-12-31 | $66.76 Million | $-23.93 Million | -0.358x | +1.51% |
| 2013-12-31 | $-42.38 Million | $15.42 Million | -0.364x | +81.67% |
| 2012-12-31 | $9.19 Million | $-18.25 Million | -1.986x | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more